

//
//
//

()

B

*

C

B

:

B

B

B

:

(% /)

(% /)

BMI

:

GGT

ALK-P, ALT, AJT

($P < /$)

Stage

viral load

HBeAg

BMI GGT

:

HBeAg

B

viral Load

B

B

:

%

B

%

()

Convenient Sampling

()

B

C

B

HBeAg

HBV-DNA (viral load) C C

B viral load

(HIV D C) C

B

() C

B

() Brunt () B

() B

HBeAg

(BMI)

GGT AIK-P ALT AST

HBV-DNA (viral load)

B

(Diasorin) ELISA HBeAg

HBV-DNA (viral load)

(Amplicor, Roche) Quantitative PCR

(Seleкта) B

/ ± / / ± / pg/ml × copies/ml
 (%) () Metavir score
 (% /) (%) ()
 HBeAg (% /) ver:13, SPSS
 (% /) T
 (% /) / P-Value

Metavir Score

HBV-DNA / ± / / ± /
 / ± / pg/ml (viral load) (% /) (% /)
 / ± / Pg/ml / ± /
 HBeAg (% /)
 Viral load Brunt %
 (P < /) %) (%)
 (P < /) (P < /) %) (%) (
 (P < /) GGT (P < /)) (%) (
 () (%

B

P value			
/	± /	/ ± /	BMI (kg/m²)
/	/ ± /	/ ± /	Cholesterol (mg/dl)
< /	/ ± /	/ ± /	Triglyceride (mg/dl)
/	/ ± /	/ ± /	FBS (mg/dl)
/	/ ± /	/ ± /	AST (IU/L)
/	/ ± /	/ ± /	ALT (IU/L)
/	/ ± /	/ ± /	Alk. Phosphatase (IU/L)
/	/ ± /	/ ± /	GGT (IU/L)

()

B C

() B

Viral load HBeAg () %

HBeAg (% / % /)

HBeAg ()

()

Viral load B

()

()

B

FBS

BMI

()

GGT ()

B GGT

()

()

()

B ()

(ALK-P, ALT, AST)

REFERENCES

1. Schiff ER, Sorell MF, Maddrey WC. Disease of the Liver. 6th ed. Philadelphia: Lippincott-Williams and Wilkins. 1999; P: 1185-97.
2. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. *Mayo Clin Proc* 1980; 55(7):434-8.
3. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. *Hepatology* 1990; 12(5):1106-10.
4. Marchesini G, Bugianesi E, Forlani G. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. *Hepatology* 2003; 37(4):917-23.
5. Diehl AM, Goodman Z, Ishak KG. Alcohol like liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. *Gastroenterology* 1988; 95(4):1056-62.
6. Patel K, Zekry A, McHutchison JG. Steatosis and chronic hepatitis C virus infection: mechanisms and significance. *Clin Liver Dis* 2005; 9(3): 399-410.
7. Harrison SA, Brunt EM, Qazi RA, Oliver DA, Neuschwander-Tetri BA, Di Bisceglie AM, et al. Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. *Clin Gastroenterol Hepatol* 2005; 3(6): 604-9.
8. Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. *Gut* 2005; 54(7): 1003-8.
9. Altıparmak E, Kol S, Yalınkılıç M, Yuksel O, Cicek B, Kayacetin E, et al. Viral and host causes of fatty liver in chronic hepatitis B. *World J Gastroenterol* 2005; 11(20): 3056-9.
10. Thomopoulos KC, Arvaniti V, Tsamantas AC, Dimitropoulou D, Gogos CA, Siagris D, et al. Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis. *Eur J Gastroenterol Hepatol* 2006; 18(3): 233-7.
11. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. *Am J Gastroenterol* 1999; 94(9):2467-74.
12. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. *Semin Liver Dis* 2001; 21(1):3-16.
13. Brunt EM, Tiniakos DG. Pathology of steatohepatitis. *Best Pract Res Clin Gastroenterol* 2002;16(5):691-707.
14. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. *Hepatology* 1996; 24(2):289-93.
15. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. *Hepatology* 1994; 20(1 Pt 1):15-20.
16. Gordon A, McLean CA, Pedersen JS, Bailey MJ, Roberts SK. Hepatic steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis. *J Hepatol* 2005; 43(1): 38-44.
17. Angulo P, Keach J, Batts K, Lindor K. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. *Hepatology* 1999; 30: 1356-62.

18. Caldwell S, Oelsner D, Iezzoni J, Hespeneide E, Battle E, Driscoll C. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. *Hepatology* 1999; 29: 664-9.
19. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of non-alcoholic fatty liver disease with insulin resistance. *Am J Med* 1999; 107:450-455.
20. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in overweight patients. *Gastroenterology* 2000; 118(6): 1117-23.